SubsidieMeestersDementia/Alzheimer Drug Attributed to Cystatin-C and other mutations – precision medicine drug development
ATI's AT-001 aims to stop and revert dementia by preventing protein aggregation, with promising Phase IIa results leading to upcoming registration trials and POC studies for commercialization.
Projectdetails
Introduction
With an aging population and over 55 million dementia cases worldwide, treatments are more needed than ever. However, effective treatments are lacking, with solutions only stalling dementia progress and no real disease-modifying effect.
Drug Development
ATI has developed AT-001, a new drug with the potential to stop and revert the disease, and to delay its onset.
Precision Medicine Platform
AT-001 has been developed through the DNACA precision-medicine based platform, which applies Big Data mining and Deep Learning/AI algorithms to identify patients with validated biomarkers.
Mechanism of Action
AT-001 is different in that it prevents aggregation of amyloid/tau proteins, common in many types of dementia.
Clinical Trials
Phase IIa clinical trials have shown strong effects in the treatment of HCCAA.
Future Plans
We will now carry out a registration trial for commercialization in Iceland and POC studies in Europe to obtain NDA in familial dementia. This will inform the treatment of Alzheimer's Disease (60% of dementia cases), potentially changing the lives of millions for the better.
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 2.500.000 |
| Totale projectbegroting | € 3.571.875 |
Tijdlijn
| Startdatum | 1-3-2023 |
| Einddatum | 28-2-2025 |
| Subsidiejaar | 2023 |
Partners & Locaties
Projectpartners
- ARCTIC THERAPEUTICS EHFpenvoerder
Land(en)
Vergelijkbare projecten binnen EIC Accelerator
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
A new cardioprotective drug for acute treatment of myocardial infarctionResoTher aims to validate RTP-026, an immunomodulating therapy, to reduce heart damage and HF risk post-myocardial infarction through Phase II clinical studies. | EIC Accelerator | € 2.499.999 | 2024 | Details |
Clear, scalable and scientific framework to measure terrestrial biodiversity3Bee leverages IoT, wildlife monitoring, and satellite data to measure and regenerate biodiversity, generating certified Biodiversity Credits for corporations to enhance ESG reporting and brand value. | EIC Accelerator | € 2.252.714 | 2024 | Details |
Novel and Scalable microbial products for REgenerative agricultureN-Spire aims to revolutionize agriculture by creating a sustainable bioactive fertilizer through innovative manufacturing techniques, enhancing soil health and reducing chemical dependency. | EIC Accelerator | € 2.499.999 | 2024 | Details |
Quantum-based Randomness Processing Units (RPUs) for High-Performance Computation and Data SecurityQuside's Randomness Processing Unit (RPU) accelerates stochastic HPC and PQ cryptography by optimizing random workloads, enhancing efficiency and performance across various sectors. | EIC Accelerator | € 2.499.999 | 2024 | Details |
A new cardioprotective drug for acute treatment of myocardial infarction
ResoTher aims to validate RTP-026, an immunomodulating therapy, to reduce heart damage and HF risk post-myocardial infarction through Phase II clinical studies.
Clear, scalable and scientific framework to measure terrestrial biodiversity
3Bee leverages IoT, wildlife monitoring, and satellite data to measure and regenerate biodiversity, generating certified Biodiversity Credits for corporations to enhance ESG reporting and brand value.
Novel and Scalable microbial products for REgenerative agriculture
N-Spire aims to revolutionize agriculture by creating a sustainable bioactive fertilizer through innovative manufacturing techniques, enhancing soil health and reducing chemical dependency.
Quantum-based Randomness Processing Units (RPUs) for High-Performance Computation and Data Security
Quside's Randomness Processing Unit (RPU) accelerates stochastic HPC and PQ cryptography by optimizing random workloads, enhancing efficiency and performance across various sectors.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Fluid Biomarkers for Neurodegenerative DementiasThe project aims to develop high-throughput biomarker tools for Alzheimer's and neurodegenerative diseases, enabling comprehensive analysis for diagnostics, drug discovery, and personalized medicine. | ERC ADG | € 2.422.973 | 2022 | Details |
Targetting neutrophil-mediated neurotoxicity for the treatment of Alzheimer's DiseaseThe NeutrAD project aims to develop and commercialize the first disease-modifying Alzheimer's drugs targeting neutrophil-mediated neurotoxicity, with promising results in preclinical models. | ERC POC | € 150.000 | 2022 | Details |
Repurposing a human drug to treat Alzheimer’s diseaseThis project aims to validate an approved drug that inhibits tau accumulation in Alzheimer's, advancing it towards commercialization as a novel treatment for the disease. | ERC POC | € 150.000 | 2022 | Details |
Novel biomarkers for improving diagnostics, prognostics, and treatments of Alzheimer’s diseaseADVANCE-AD aims to enhance Alzheimer's diagnostics and treatment by developing cost-effective blood-based biomarkers and algorithms for early detection and intervention in pre-symptomatic patients. | ERC ADG | € 2.500.000 | 2024 | Details |
Fluid Biomarkers for Neurodegenerative Dementias
The project aims to develop high-throughput biomarker tools for Alzheimer's and neurodegenerative diseases, enabling comprehensive analysis for diagnostics, drug discovery, and personalized medicine.
Targetting neutrophil-mediated neurotoxicity for the treatment of Alzheimer's Disease
The NeutrAD project aims to develop and commercialize the first disease-modifying Alzheimer's drugs targeting neutrophil-mediated neurotoxicity, with promising results in preclinical models.
Repurposing a human drug to treat Alzheimer’s disease
This project aims to validate an approved drug that inhibits tau accumulation in Alzheimer's, advancing it towards commercialization as a novel treatment for the disease.
Novel biomarkers for improving diagnostics, prognostics, and treatments of Alzheimer’s disease
ADVANCE-AD aims to enhance Alzheimer's diagnostics and treatment by developing cost-effective blood-based biomarkers and algorithms for early detection and intervention in pre-symptomatic patients.